Clinical applications of 1H-MR spectroscopy in the evaluation of epilepsies--what do pathological spectra stand for with regard to current results and what answers do they give to common clinical questions concerning the treatment of epilepsies?

Acta Neurol Scand. 2003 Oct;108(4):223-38. doi: 10.1034/j.1600-0404.2003.00152.x.

Abstract

Nuclear magnetic resonance spectroscopy (1H-MRS) is a non-invasive method in detecting abnormal spectra of various brain metabolites containing N-acetylaspartate (NAA), Choline (Cho), Creatine (Cr), gamma-Aminobutyric acid (GABA) and Glutamate. Technical processing of the MR-systems, improved automated shimming methods and further development of special shim coils increase the magnetic field homogeneity and lead to a better spectral quality and spectral resolution. The handling of the systems becomes more user-friendly and is more likely to be used in routine diagnostics. The 1H-MRS has become a diagnostic tool for assessing a number of diseases of the central nervous system mainly including epilepsies and brain tumours. The role of 1H-MRS in the assessment of epilepsies will probably increase in future. In the following article, the principles of 1H-MRS and an overview of it in the evaluation and treatment of epilepsies with special regard to temporal lobe epilepsies (TLE) has been illustrated.

Publication types

  • Review

MeSH terms

  • Brain / pathology
  • Brain Chemistry
  • Epilepsy / pathology*
  • Epilepsy / therapy*
  • Humans
  • Magnetic Resonance Spectroscopy*
  • Reproducibility of Results